Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

A systematic review of best practices in HIV care.

Maina G, Mill J, Chaw-Kant J, Caine V.

J HIV AIDS Soc Serv. 2016 Mar 22;15(1):114-126.

2.

Timing, rates, and causes of death in a large South African tuberculosis programme.

Field N, Lim MS, Murray J, Dowdeswell RJ, Glynn JR, Sonnenberg P.

BMC Infect Dis. 2014 Dec 21;14:3858. doi: 10.1186/s12879-014-0679-9.

3.

Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.

Johnston V, Cohen K, Wiesner L, Morris L, Ledwaba J, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD.

J Infect Dis. 2014 Mar 1;209(5):711-20. doi: 10.1093/infdis/jit411.

4.

Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.

Hoffmann CJ, Ledwaba J, Li JF, Johnston V, Hunt G, Fielding KL, Chaisson RE, Churchyard GJ, Grant AD, Johnson JA, Charalambous S, Morris L.

Antivir Ther. 2013;18(7):915-20. doi: 10.3851/IMP2652.

5.

Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.

Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ.

PLoS One. 2013 May 14;8(5):e64459. doi: 10.1371/journal.pone.0064459.

6.

The impact of HIV, an antiretroviral programme and tuberculosis on mortality in South African platinum miners, 1992-2010.

Lim MS, Dowdeswell RJ, Murray J, Field N, Glynn JR, Sonnenberg P.

PLoS One. 2012;7(6):e38598. doi: 10.1371/journal.pone.0038598.

7.

Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome.

Johnston V, Fielding K, Charalambous S, Mampho M, Churchyard G, Phillips A, Grant AD.

PLoS One. 2012;7(5):e36997. doi: 10.1371/journal.pone.0036997.

8.

A novel HIV treatment model using private practitioners in South Africa.

Innes C, Hamilton R, Hoffmann CJ, Hippner P, Fielding K, Grant AD, Churchyard GJ, Charalambous S.

Sex Transm Infect. 2012 Mar;88(2):136-40. doi: 10.1136/sextrans-2011-050194.

9.

Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa.

El-Khatib Z, Delong AK, Katzenstein D, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Petzold M, Morris L, Kantor R.

J AIDS Clin Res. 2011 Feb 18;2(117). pii: 1000117.

10.

Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.

Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, Fielding KL, Churchyard GJ.

AIDS. 2010 Nov;24 Suppl 5:S5-13. doi: 10.1097/01.aids.0000391010.02774.6f.

11.

Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study.

Russell EC, Charalambous S, Pemba L, Churchyard GJ, Grant AD, Fielding K.

BMC Public Health. 2010 Jul 23;10:433. doi: 10.1186/1471-2458-10-433.

12.

Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial.

Sanne I, Orrell C, Fox MP, Conradie F, Ive P, Zeinecker J, Cornell M, Heiberg C, Ingram C, Panchia R, Rassool M, Gonin R, Stevens W, Truter H, Dehlinger M, van der Horst C, McIntyre J, Wood R; CIPRA-SA Study Team..

Lancet. 2010 Jul 3;376(9734):33-40. doi: 10.1016/S0140-6736(10)60894-X. Erratum in: Lancet. 2010 Sep 25;376(9746):1054.

13.

Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa.

Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson RE, Fielding KL, Churchyard GJ, Morris L, Grant AD.

Clin Infect Dis. 2009 Dec 15;49(12):1928-35. doi: 10.1086/648444.

14.

Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program.

Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, Grant AD, Fielding KL, Thio CL.

Clin Infect Dis. 2008 Dec 1;47(11):1479-85. doi: 10.1086/593104.

15.

Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study.

Fielding KL, Charalambous S, Stenson AL, Pemba LF, Martin DJ, Wood R, Churchyard GJ, Grant AD.

BMC Infect Dis. 2008 Jul 16;8:93. doi: 10.1186/1471-2334-8-93.

16.

Streamlining tasks and roles to expand treatment and care for HIV: randomised controlled trial protocol.

Fairall LR, Bachmann MO, Zwarenstein MF, Lombard CJ, Uebel K, van Vuuren C, Steyn D, Boulle A, Bateman ED.

Trials. 2008 Apr 23;9:21. doi: 10.1186/1745-6215-9-21.

17.

Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.

Hoffmann CJ, Fielding KL, Charalambous S, Sulkowski MS, Innes C, Thio CL, Chaisson RE, Churchyard GJ, Grant AD.

AIDS. 2008 Jan 2;22(1):67-74.

18.

Attitudes to directly observed antiretroviral treatment in a workplace HIV care programme in South Africa.

Page-Shipp LS, Charalambous S, Roux S, Dias B, Sefuti C, Churchyard GJ, Grant AD.

Sex Transm Infect. 2007 Aug;83(5):383-6.

Supplemental Content

Support Center